3
Oct 21 (Reuters) – Fortress Biotech Inc: * FORTRESS BIOTECH AND SUBSIDIARY URICA THERAPEUTICS ANNOUNCE FIRST PATIENTS DOSED IN CRYSTALYS THERAPEUTICS’ GLOBAL PHASE 3 TRIALS OF DOTINURAD FOR THE TREATMENT OF GOUT Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
